Reem Saad Almaghrabi

Reem Saad Almaghrabi

Auto-generated profile, based on publicly available information

Reem Saad Almaghrabi

Kidney and Pancreas Health Centre, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
ARAli A. Rabaan
Ali A. Rabaan
TSTarek Sulaiman
Tarek Sulaiman
SAShamsah H. Al-Ahmed
Shamsah H. Al-Ahmed
ZBZainab A. Buhaliqah
Zainab A. Buhaliqah
ABAli Ahmed Buhaliqah
Ali Ahmed Buhaliqah
Ranjan K. MohapatraRanjan K. Mohapatra
Ranjan K. Mohapatra
Fungal infections are becoming one of the main causes of morbidity and mortality in people with weakened immune systems. Mycoses are becoming more common, despite greater knowledge and better treatment methods, due to the regular emergence of resistance to the antifungal medications used in clinical settings. Antifungal therapy is the mainstay of patient management for acute and chronic mycoses. However, the limited availability of antifungal drug classes limits the range of available treatments. Additionally, several drawbacks to treating mycoses include unfavourable side effects, a limited activity spectrum, a paucity of targets, and fungal resistance, all of which continue to be significant issues in developing antifungal drugs. The emergence of antifungal drug resistance has eliminated accessible drug classes as treatment choices, which significantly compromises the clinical management of fungal illnesses. In some situations, the emergence of strains resistant to many antifungal medications is a major concern. Although new medications have been developed to address this issue, antifungal drug resistance has grown more pronounced, particularly in patients who need long-term care or are undergoing antifungal prophylaxis. Moreover, the mechanisms that cause resistance must be well understood, including modifications in drug target affinities and abundances, along with biofilms and efflux pumps that diminish intracellular drug levels, to find novel antifungal drugs and drug targets. In this review, different classes of antifungal agents, and their resistance mechanisms, have been discussed. The latter part of the review focuses on the strategies by which we can overcome this serious issue of antifungal resistance in humans.

18 February 2020 in Mycoses
Verified
Journal Article
Closed access
PDF file
RAReem S. Almaghrabi
Reem S. Almaghrabi
RARashed Albalawi
Rashed Albalawi
MMMaysoon Mutabagani
Maysoon Mutabagani
EAEdwin Atienza
Edwin Atienza
SASuliman Aljumaah
Suliman Aljumaah
SASahar Althawadi
Sahar Althawadi

5 March 2023 in Medicina
Verified
Journal Article
Open access
PDF file
ARAli A. Rabaan
Ali A. Rabaan
SAShamsah H. Al-Ahmed
Shamsah H. Al-Ahmed
HAHawra Albayat
Hawra Albayat
SASara Alwarthan
Sara Alwarthan
MAMashael Alhajri
Mashael Alhajri
Manish DhawanManish Dhawan
Manish Dhawan
The immune response elicited by the current COVID-19 vaccinations declines with time, especially among the immunocompromised population. Furthermore, the emergence of novel SARS-CoV-2 variants, particularly the Omicron variant, has raised serious concerns about the efficacy of currently available vaccines in protecting the most vulnerable people. Several studies have reported that vaccinated people get breakthrough infections amid COVID-19 cases. So far, five variants of concern (VOCs) have been reported, resulting in successive waves of infection. These variants have shown a variable amount of resistance towards the neutralising antibodies (nAbs) elicited either through natural infection or the vaccination. The spike (S) protein, membrane (M) protein, and envelope (E) protein on the viral surface envelope and the N-nucleocapsid protein in the core of the ribonucleoprotein are the major structural vaccine target proteins against COVID-19. Among these targets, S Protein has been extensively exploited to generate effective vaccines against COVID-19. Hence, amid the emergence of novel variants of SARS-CoV-2, we have discussed their impact on currently available vaccines. We have also discussed the potential roles of S Protein in the development of novel vaccination approaches to contain the negative consequences of the variants’ emergence and acquisition of mutations in the S Protein of SARS-CoV-2. Moreover, the implications of SARS-CoV-2’s structural proteins were also discussed in terms of their variable potential to elicit an effective amount of immune response.

13 April 2017 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
RAReem S. Almaghrabi
Reem S. Almaghrabi
AOAli Omrani
Ali Omrani
ZMZiad Memish
Ziad Memish
Introduction: Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in solid organ transplant (SOT) patients. Lung transplant recipients are particularly at risk given the intense immunosuppression required. Areas covered: The Detailed review of the literature related to CMV infection, its direct and indirect effect on lung allograft function, as well as diagnosis, immune monitoring, treatment options and prevention strategies. Expert commentary: In lung transplant recipients, CMV infection is associated with pro-inflammatory and immune inhibitory effects that increase the risk of graft dysfunction and loss. Diagnosis of CMV infection remains challenging. Treatment options remain relatively limited.

15 May 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
FAFeda Alsuwairi
Feda Alsuwairi
AAAsma Alsaleh
Asma Alsaleh
MAMadain Saleh Alsanea
Madain Saleh Alsanea
AAAhmed Al-Qahtani
Ahmed Al-Qahtani
DODalia Obeid
Dalia Obeid
FAFatimah Saeed Alhamlan
Fatimah Saeed Alhamlan
SARS-CoV-2 genomic mutations outside the spike protein that may increase transmissibility and disease severity have not been well characterized. This study identified mutations in the nucleocapsid protein and their possible association with patient characteristics. We analyzed 695 samples from patients with confirmed COVID-19 in Saudi Arabia between 1 April 2021, and 30 April 2022. Nucleocapsid protein mutations were identified through whole genome sequencing. 𝜒2 tests and t tests assessed associations between mutations and patient characteristics. Logistic regression estimated the risk of intensive care unit (ICU) admission or death. Of the 60 mutations identified, R203K was the most common, followed by G204R, P13L, E31del, R32del, and S33del. These mutations were associated with reduced risk of ICU admission. P13L, E31del, R32del, and S33del were also associated with reduced risk of death. By contrast, D63G, R203M, and D377Y were associated with increased risk of ICU admission. Most mutations were detected in the SR-rich region, which was associated with low risk of death. The C-tail and central linker regions were associated with increased risk of ICU admission, whereas the N-arm region was associated with reduced ICU admission risk. Consequently, mutations in the N protein must be observed, as they may exacerbate viral infection and disease severity. Additional research is needed to validate the mutations’ associations with clinical outcomes.

30 March 2018 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
SASultan Alsobayeg
Sultan Alsobayeg
NANada Alshehri
Nada Alshehri
SMShamayel Mohammed
Shamayel Mohammed
BFBahaa M. Fadel
Bahaa M. Fadel
AOAli Omrani
Ali Omrani
RAReem S. Almaghrabi
Reem S. Almaghrabi